Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

Pubblicato online: 25 apr 2014

Pagine: 184 - 188

Ricevuto: 27 ago 2013

Accettato: 18 nov 2013

DOI: https://doi.org/10.2478/raon-2013-0083

Parole chiave

breast cancer, Her2/neu, trastuzumab, bevacizumab, VEGF

© by Robert Königsberg

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.